HONG KONG – Standing out of a crowd of more than 200 next-generation sequencing (NGS) product developers in China, a 20-month-old company raised ¥150 million (US$23 million) in a follow-up series A financing and struck a partnership deal with U.S. genomics leader Illumina Inc.